摘要
叶酸(FA)对三种叶酸受体(FRS)亚型具有高亲和力,分别是:FRα、FRβ和FRγ。其中,FRα是肿瘤特异性受体,它在各种肿瘤中经常过表达而在正常组织中不表达。在这项研究中,我们结合叶酸到一种壳聚糖聚(乙烯亚胺)共聚物中,并证实了该产品(即“CP1.3K-FA”)在肿瘤细胞中的低细胞毒性。转染发实验证明,在最佳条件下,对CP1.3K-FA转染效率高于未改性的壳聚糖聚(乙烯亚胺)共聚物。荧光素酶活性检测结果也表明,CP1.3K-FA转染效率可以与B16和U87细胞中的Fugene HD相比较。我们的研究结果表明,CP1.3K-FA将进一步发展为肿瘤细胞基因传递的载体
关键词: 壳聚糖,叶酸,基因转移,非病毒载体,聚(乙烯亚胺),靶向。
Current Gene Therapy
Title:Folate-conjugated Chitosan-poly(ethylenimine) Copolymer As An Efficient and Safe Vector For Gene Delivery in Cancer Cells
Volume: 15 Issue: 5
Author(s): Wing-Fu Lai and Marie C. Lin
Affiliation:
关键词: 壳聚糖,叶酸,基因转移,非病毒载体,聚(乙烯亚胺),靶向。
摘要: Folic acid (FA) has high affinity to folate receptors (FRs), which have three isoforms: FRα, FRβ and FRγ. Among them, FRα is a tumor specific receptor, as it is frequently over-expressed in diverse malignancies but not in normal tissues. In this study, we have conjugated FA to a chitosan-poly(ethylenimine) copolymer, and have confirmed the low cytotoxicity of the product (namely “CP1.3K-FA”) in cancer cells. The transfection efficiency of CP1.3K-FA has been shown by the EGFP transfection assay to be higher than that of the unmodified chitosan-poly(ethylenimine) copolymer under optimal conditions. Results of the luciferase activity assay have also indicated that the transfection efficiency of CP1.3K-FA is comparable to that of Fugene HD in B16 and U87 cells. Our results have suggested that CP1.3K-FA warrants further development as a vector for gene delivery in cancer cells.
Export Options
About this article
Cite this article as:
Lai Wing-Fu and Lin C. Marie, Folate-conjugated Chitosan-poly(ethylenimine) Copolymer As An Efficient and Safe Vector For Gene Delivery in Cancer Cells, Current Gene Therapy 2015; 15 (5) . https://dx.doi.org/10.2174/1566523215666150812120347
DOI https://dx.doi.org/10.2174/1566523215666150812120347 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for
the Identification of Phyto-derived ATP-Competitive Inhibitors of the
BCR-ABL Kinase Domain
Current Drug Discovery Technologies Research Progress on hCNT3 Structure/Function and Nucleoside Anticancer Drugs
Current Protein & Peptide Science Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design Pro-inflammatory Cytokines in Animal and Human Gestation
Current Pharmaceutical Design N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Current Cancer Drug Targets Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets Approaches to Quantification of RNA Targets by PCR Based Techniques
Current Genomics Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?
Current HIV Research Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Current Pharmaceutical Design Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry